Exhibit 1A-6.6

Memorandum of Understanding (MOU)

This Memorandum of Understanding (“MoU”) is entered into as of July 15^th 2025 (the “Effective Date”), by and between:

FirstVitals Inc. (“FirstVitals”), a Delaware corporation with its principal place of business located in Danville, California, USA,

and

Augere Medical AS (“Augere” or the “Company”), a Norwegian private limited company with its registered address in Oslo, Norway, (each a “Party” and together, the “Parties”)

This MoU sets out a high-level understanding between FirstVitals and Augere Medical AS to collaborate on investment, product development, and commercialisation opportunities in advanced AI-enabled diagnostics and endoscopy.

Our shared aim is to advance clinically validated, AI powered gastrointestinal solutions in both humans and animals, in a way that compounds value, builds collaborative synergy and leverages each party’s unique strengths.

We’re aligned on what matters: shared values, expert execution, and speed. This MoU helps us mitigate risks quickly, deliver early value, and move with intent. The leverage for execution on technology advancement. It will unlock a new clinical indication for Barrett’s Esophagus, technical feasibility for equine use, and early regulatory traction across targeted geographies.

Both Parties bring unique and complementary strength to this collaboration: Augere contributes deep expertise in AI development, clinical validation, regulatory expertise and international commercialisation, while FirstVitals brings strategic capital, US regulatory and commercial know how and experience in capsule platform deployment. This MoU reflects a shared commitment to mutual success, and both parties agree that contributions will be fairly recognised in investor communications, product development and strategic planning.

The Parties acknowledge and agree that all obligations, undertakings, and milestones contemplated by this Memorandum of Understanding are expressly conditional upon FirstVitals’ successful completion of its pending Regulation A capital raise (the “Reg A Offering”).

A. Augere Pre-Series A Investment

B. Veterinary Capsule AI Development

C. Human Capsule AI Development – Small-Bowel Indication

C-1 Development Budget: cost-plus-estimated target-fee

C-2 Annual Service & Improvement Fee (ASF)

C-3 Running Royalty (creditable against ASF)

Mechanics. On an annual basis, FirstVitals will (i) calculate royalties due, (ii) deduct them from that year’s ASF until the ASF is exhausted, and (iii) remit any excess royalty balance. If annual royalties exceed the ASF, no further ASF is payable for that year.

C-4 Additional Indications

For each future indication elected by FirstVitals:

C-5 Audit and Adjustment

Augere shall supply an audited cost statement within 30 days of each milestone. Any undisputed cost underrun will reduce the ceiling dollar-for-dollar; overruns require mutual written approval.

D. Series A & Barrett’s Development

In addition to standard royalty terms, the Parties may agree to tiered success-based royalties in the Definitive Agreements. These would be triggered by surpassing defined revenue milestones for either the human AI solution, veterinary AI solution or the Barrett’s detection platform. This mechanism is intended to reward accelerated commercialisation and align incentives for scaling impact.

This MoU is intended to form the foundation of two binding documents to be negotiated and executed:

The final terms, including any governance rights, exclusivity terms, and performance incentives, will be defined in these agreements.

Veterinary Capsule Industry: FirstVitals will receive perpetual exclusive rights for worldwide commercialisation of the veterinary markets including but not limited to companion pets, and equine AI capsule technology, as defined in the Product Development Agreement. Rights will include all derivative and improvement technologies required for commercialisation. FirstVitals is willing to negotiate conditional exclusive distribution rights for a possible veterinary capsule technology for Augere in Europe.

Human Capsule Industry: FirstVitals will receive perpetual exclusive rights for worldwide commercialisation of the human AI capsule technology, as defined in the Product Development Agreement. Rights will include all derivative and improvement technologies required for commercialisation. FirstVitals is willing to negotiate conditional exclusive distribution rights for the human capsule technology for Augere in Europe.

Barrett’s / AIGI™ Platform: If FirstVitals serves as lead investor in the Series A round, defined as contributing at least 50% of the round total, it shall be granted a Conditional Exclusivity for exclusive U.S. commercial rights to the AIGI™ detection platform (combining AI polyp detection and AI Barrett’s esophagus diagnosis). This conditional exclusivity for U.S. commercial rights shall apply for a period of 24 months following FDA clearance, with a one-time extension of 12 months subject to achievement mutually agreed performance milestones. If FirstVitals does not serve as lead investor, this right shall not apply, and Augere may pursue other strategic partnerships for U.S. commercialisation.

Any grant of exclusive or negotiated U.S. commercial rights shall include a licensing fee, payable to Augere as defined in the definitive agreement. Additionally, performance-based bonus payment will be agreed based on key commercial milestones, such as first sales or revenue thresholds, to reflect the strategic value of these rights.

This MoU shall be governed by the laws of England, chosen as neutral and mutually acceptable jurisdiction.

Any disputes arising from this MoU shall be resolved through confidential arbitration in London, in accordance with the rules of the London Court of International Arbitration (LCIA). The arbitration shall be conducted in English.

This MoU will remain effective until July 31^st, 2025, unless extended by mutual agreement. Either Party may terminate this MoU with 20 days’ written notice in the event of:

Termination of this MoU will not affect obligations relating to confidentiality or IP sharing.

Each Party agrees to maintain the confidentiality of any proprietary or commercially sensitive information exchanged for a period of three (3) years from the date of disclosure.

Unless explicitly agreed otherwise in writing:

Page 6 of 6